Structure Therapeutics Inc ADR (NASDAQ: GPCR) stock jumped 12.14% on Friday to $53.77 against a previous-day closing price of $47.95. With 1.06 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.91 million shares. The 52-week range on GPCR shows that it touched its highest point at $75.02 and its lowest point at $20.80 during that stretch. It currently has a 1-year price target of $89.17.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GPCR was down-trending over the past week, with a drop of -2.00%, but this was down by -19.70% over a month. Three-month performance surged to 85.35% while six-month performance rose 121.82%. A look at the trailing 12-month EPS for GPCR yields -2.30 with Next year EPS estimates of -0.99. For the next quarter, that number is -0.21. This implies an EPS growth rate of 83.56% for this year and -14.74% for next year.
Float and Shares Shorts:
At present, 36.59 million GPCR shares are outstanding with a float of 32.69 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.74 million, which was 6.20% higher than short shares on Sep 28, 2023. In addition to Dr. Raymond C. Stevens Ph.D. as the firm’s CEO & Director, Dr. Yingli Ma Ph.D. serves as its Chief Technology Officer.
Institutional Ownership:
Through their ownership of 41.29% of GPCR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 50.95% of GPCR, in contrast to 18.84% held by mutual funds. As the largest shareholder in GPCR with 6.01% of the stake, T. Rowe Price Associates, Inc. holds 2,513,563 shares worth 2,513,563. A second-largest stockholder of GPCR, Driehaus Capital Management LLC, holds 2,388,876 shares, controlling over 5.72% of the firm’s shares. Janus Henderson Investors US LLC is the third largest shareholder in GPCR, holding 1,943,918 shares or 4.65% stake. With a 1.70% stake in GPCR, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 709,313 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Small C, which owns about 1.41% of GPCR stock, is the second-largest Mutual Fund holder. It holds 587,500 shares valued at 43.65 million. Federated Hermes Kaufmann Fund holds 1.20% of the stake in GPCR, owning 500,000 shares worth 37.15 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GPCR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GPCR analysts setting a high price target of $97.00 and a low target of $79.00, the average target price over the next 12 months is $89.17. Based on these targets, GPCR could surge 80.4% to reach the target high and rise by 46.92% to reach the target low. Reaching the average price target will result in a growth of 65.84% from current levels.
